Skip to main content
Clinical Trials/NCT03394079
NCT03394079
Active, not recruiting
Not Applicable

A Prospective, Open Label, Multi-center, Dual Arm, Randomized, Pragmatic Trial : Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention

Seung-Jung Park9 sites in 1 country2,008 target enrollmentApril 12, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Vessels
Sponsor
Seung-Jung Park
Enrollment
2008
Locations
9
Primary Endpoint
Rate of target vessel failure
Status
Active, not recruiting
Last Updated
4 months ago

Overview

Brief Summary

The primary aim of this study is to compare the clinical efficacy and safety of OCT-guided(optical coherence tomography (OCT)-guided) and IVUS-guided(Intravascular ultrasound (IVUS)-guided) strategies in patients undergoing Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) or drug-coated balloons (only for in-stent restenosis) for significant obstructive Coronary artery disease (CAD).

The investigators hypothesize that OCT-guided PCI is non-inferior to IVUS-guided PCI with respect to primary end point of target-vessel failure (cardiac death, target-vessel myocardial infarction [MI], or ischemia-driven target-vessel revascularization [TVR]) at 1 year after randomization.

Registry
clinicaltrials.gov
Start Date
April 12, 2018
End Date
January 31, 2027
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Seung-Jung Park
Responsible Party
Sponsor Investigator
Principal Investigator

Seung-Jung Park

Professor, Division of Cardiology, Division of Cardiology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • Men or women at least 19 years of age
  • Subjects with obstructive CAD undergoing PCI with contemporary DES or drug-coated balloons (only for in-stent restenosis) under intracoronary imaging guidance.
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria

  • ST-elevation myocardial infarction
  • Severe renal dysfunction (eGFR \<30 ml/min/1.73 m2 or serum creatinine level \>1.5 mg/dl), unless patient is on renal replacement therapy.
  • Cardiogenic shock or decompensated heart failure with severe LV dysfunction (LVEF) \< 30%
  • Life expectancy \< 1 year for any non-cardiac or cardiac causes
  • Any lesion characteristics resulting in the expected inability to deliver the IVUS or OCT catheter to the lesion pre- and post-PCI (eg, moderate or severe vessel calcification or tortuosity)
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
  • Unwillingness or inability to comply with the procedures described in this protocol

Outcomes

Primary Outcomes

Rate of target vessel failure

Time Frame: 1 year

A composite of cardiac death, target-vessel MI or ischemia-driven TVR) at 1 year after randomization. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.

Secondary Outcomes

  • Rate of stent thrombosis(1, and 5 years)
  • Rate of target-lesion failure(1, and 5 years)
  • Rate of angiographic or imaging-based device success(1 day)
  • Rate of cardiac Death(1, and 5 years)
  • Rate of death(1, and 5 years)
  • Rate of repeat revascularization(1, and 5 years)
  • Rate of any hospitalization(1, and 5 years)
  • Rate of myocardial infarction(1, and 5 years)
  • Rate of target vessel myocardial infarction(1, and 5 years)
  • Rate of ischemia-driven target vessel revascularization(1, and 5 years)
  • Rate of contrast-induced acute kidney injury(3 days)
  • Rate of stroke(1, and 5 years)
  • Rate of bleeding events(1, and 5 years)
  • Rate of procedural complications requiring active intervention that were related to PCI or intracoronary imaging devices(1 day)

Study Sites (9)

Loading locations...

Similar Trials